phenoxy-thiocarbonyl chloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: phenoxy-thiocarbonyl chloride
• 英文别名: phenyloxythiocarbonyl chloride；S-phenoxy chloromethanethioate
• 化学式: C₇H₅ClO₂S
• 分子量: 188.635
• InChiKey: XQPAMHLJWPSEEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-二甲氨基吡啶 、 phenoxy-thiocarbonyl chloride 以 二氯甲烷 、 乙腈 为溶剂， 生成 正己烷
  参考文献：
  名称：

  Desazapurine-nucleotide derivatives, processes for the preparation thereof, pharmaceutical compositions containing them and the use thereof for nucleic acid sequencing and as antiviral agents

  摘要：

  本发明提供了一般式为的脱氮嘧啶-核苷衍生物：其中X是氮原子或甲烷基，W是氮原子或C-R4基团，R1、R2、R3和R4可以相同也可以不同，是氢或卤素原子、羟基或巯基、低级烷基、低级烷基硫、低级烷氧基、芳基烷基、芳基烷氧基或芳氧基基团或氨基，可以选择性地被取代一次或两次，R5是氢原子或羟基，R6和R7分别是氢原子或其中一个是卤素原子或氰基或叠氮基或氨基，可以选择性地被取代一次或两次，其中当X是甲烷基时，R6和R7中的一个也可以是羟基，此外，R5和R7也可以一起表示C-2'和C-3'之间的进一步价键，Y是氢原子或单、双或三磷酸酯基。

  公开号：

  US06211158B1
• 作为试剂：
  描述：

  5-甲基尿甙 在 chromium(VI) oxide 、 甲醇 、 sodium hydroxide 、 phenoxy-thiocarbonyl chloride 、 偶氮二异丁腈 、 四丁基氟化铵 、 三正丁基氢锡 、 乙酸酐 作用下， 以 四氢呋喃 、 吡啶 为溶剂， 生成 5'-O-(t-butyldimethylsilyl)-3'-C-cyano-3'-deoxythymidine
  参考文献：
  名称：

  3′--Cyano-3′-deoxythymidine

  摘要：

  DOI：

  10.1016/s0040-4039(00)82488-0

文献信息

• Certain chroman derivatives useful for treating symptoms caused by
  申请人：Nippon Kayaku Kabushiki Kaisha

  公开号：US05296492A1

  公开（公告）日：1994-03-22

  A chroman derivative represented by the following general formula [1]: ##STR1## wherein R.sub.1 represents cyano group, nitro group, halogenomethyl group or --SO.sub.2 --X group (X represents lower alkyl group having 1-6 carbon atoms or aryl group); R.sub.2 represents hydrogen atom or OA group (A represents hydrogen atom, nitro group, lower acyl group having 1-6 carbon atoms, arylcarbonyl group, lower alkylsulfonyl group having 1-6 carbon atoms, arylsulfonyl group, arylalkyl group, tetrahydropyranyl group, lower alkoxycarbonyl group having 1-6 carbon atoms, arylalkoxycarbonyl group or silyl derivative group); R.sub.3 singly represents a hydrogen atom; or R.sub.3 forms a bond jointly with R.sub.2 ; and R.sub.4, R.sub.5, R.sub.6 and R.sub.7 each represent hydrogen atom, vinyl group, formyl group, --Y--(OA).sub.n group (Y represents straight or branched chain alkylene group having 1-6 carbon atoms or lower alkenyl group having 1-6 carbon atoms, A is as defined above, and n represents an integer of 1-3. The compound of this invention is expected to be effectively usable as an agent for treatment of various symptoms due to the contraction of smooth muscles, for treatment of the diseases of the circulatory system and for treatment of epilepsy.

  以下是通用公式[1]表示的一种色酮衍生物：##STR1##其中R.sub.1代表氰基、硝基、卤代甲基基团或--SO.sub.2--X基团（X代表具有1-6个碳原子的较低烷基基团或芳基团）；R.sub.2代表氢原子或OA基团（A代表氢原子、硝基、具有1-6个碳原子的较低酰基基团、芳基羰基基团、具有1-6个碳原子的较低烷基磺酰基团、芳基磺酰基团、芳基烷基基团、四氢吡喃基团、具有1-6个碳原子的较低烷氧羰基团、芳基烷氧羰基团或硅基衍生物基团）；R.sub.3单独代表氢原子；或R.sub.3与R.sub.2共同形成键；而R.sub.4、R.sub.5、R.sub.6和R.sub.7分别代表氢原子、乙烯基、甲酰基、--Y--(OA).sub.n基团（Y代表具有1-6个碳原子的直链或支链烷基基团或具有1-6个碳原子的较低烯基基团，A如上定义，n代表1-3的整数）。本发明的化合物预计可有效用作治疗由于平滑肌收缩引起的各种症状的药剂，治疗循环系统疾病和治疗癫痫。
• Heterocyclic derivative and pharmaceutical composition comprising the same
  申请人：Kai Hiroyuki

  公开号：US09212130B2

  公开（公告）日：2015-12-15

  The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect. A pharmaceutical composition having a P2X3 and/or P2X2/3 receptor antagonistic effect comprising a compound of the formula (I): wherein ring A is substituted or unsubstituted 5 to 7-membered cycloalkane, substituted or unsubstituted 5 to 7-membered cycloalkene or the like; C is a carbon atom; —X— is —N(R16)— or the like; R16 is hydrogen, substituted or unsubstituted alkyl or the like; R7 is substituted or unsubstituted 5- or 6-membered heteroaryl, substituted or unsubstituted 6 to 10 membered aryl; Q1 and Q2 are each independently a carbon atom or a nitrogen atom; -L- is —O—, —S— or the like; R6 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl or the like; R2 is hydrogen, hydroxy or the like, or its pharmaceutically acceptable salt or a solvate thereof.

  本发明提供了具有P2X3和/或P2X2/3受体拮抗作用的新化合物。具有P2X3和/或P2X2/3受体拮抗作用的药物组合物包括式(I)的化合物：其中环A是取代或未取代的5至7成员环烷烃，取代或未取代的5至7成员环烯烃等；C是碳原子；-X-是-N(R16)-等；R16是氢、取代或未取代的烷基等；R7是取代或未取代的5-或6-成员杂芳基，取代或未取代的6至10成员芳基；Q1和Q2分别是碳原子或氮原子；-L-是-O-、-S-等；R6是取代或未取代的环烷基，取代或未取代的环烯基等；R2是氢、羟基等，或其药学上可接受的盐或溶剂化合物。
• Methods of treating hepatitis delta virus infection with beta-l-2'-deoxy-nucleosides
  申请人：——

  公开号：US20020035085A1

  公开（公告）日：2002-03-21

  A method and composition for treating a host infected with hepatitis D comprising administering an effective hepatitis D treatment amount of a described 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof.

  一种治疗感染乙型肝炎的宿主的方法和组合物，包括给予所述2'-脱氧-β-L-赤霉糖核苷或其药用可接受的盐或前药的有效乙型肝炎治疗剂量。
• Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides
  申请人：——

  公开号：US20030144502A1

  公开（公告）日：2003-07-31

  A purine nucleoside analog includes a pyrido[2,3-d]pyrimidine or a pyrimido[4,5-d]pyrimidine and further has a sugar moiety that is optionally modified at the C2′, C3′, C4′ and/or C5′ position. Particularly contemplated compounds also include prodrug forms of the purine nucleoside analogs, and both purine nucleoside analogs and the corresponding prodrugs are employed in the reduction of growth of neoplastic cells.

  一种嘌呤核苷类似物包括吡啶并［2,3-d］嘧啶或嘧啶并［4,5-d］嘧啶，进一步具有一个糖基团，在C2′、C3′、C4′和/或C5′位置可以选择性地被修饰。特别考虑的化合物还包括嘌呤核苷类似物的前药形式，嘌呤核苷类似物和相应的前药都用于抑制肿瘤细胞的生长。
• PROCESS FOR PRODUCING NUCLEIC ACID DERIVATIVES
  申请人：——

  公开号：US20020045744A1

  公开（公告）日：2002-04-18

  There can be provided an excellent industrial process for producing compounds having sugar-moiety hydroxyl groups or halogen atoms reduced in nucleic acids or in derivatives thereof by allowing O-thiocarbonyl derivatives of sugar-moiety hydroxyl groups or allowing halogenated derivatives in the sugar-moiety, in the nucleic acids or in derivatives thereof to react with any one of hypophosphorous acids (including salts thereof) and phosphites (esters) which are inexpensive, non-toxic and safely usable as radical reducing agents in industrial scale, in the presence of a radical reaction initiator. The process of the present invention is an industrially useful and highly safe process for reducing sugar-moiety hydroxyl groups and halogen atoms in nucleic acids or derivatives thereof (including nucleic acid-related compounds) at low costs.

  可以提供一个出色的工业过程，用于通过允许具有糖基羟基或卤原子的化合物在核酸或其衍生物中减少，通过允许糖基羟基的O-硫酰衍生物或在核酸中或其衍生物中允许卤代衍生物与任何一种廉价、无毒且安全可用作工业规模中的自由基还原剂的次磷酸（包括其盐）和磷酸酯（酯）反应，在自由基反应引发剂的存在下。本发明的工艺是一种在低成本下减少核酸或其衍生物（包括核酸相关化合物）中的糖基羟基和卤原子的工业上有用且高度安全的过程。